| Literature DB >> 31509959 |
Chunlei Zhang1, Adeola M Alashi1, Nisha Singh2, Prashen Chelikani2, Rotimi E Aluko3.
Abstract
Being averse to bitter taste is a common phenomenon for humans and other animals, which requires the pharmaceutical and food industries to source compounds that can block bitterness intensity and increase consumer acceptability. In this work, beef protein alcalase hydrolysates (BPAH) and chymotrypsin hydrolysates (BPCH) were reacted with glucose to initiate Maillard reactions that led to the formation of glycated or advanced glycation end products (AGEs), BPAH-AGEs and BPCH-AGEs, respectively. The degree of glycation was higher for the BPAH-AGEs (47-55%) than the BPCH-AGEs (30-38%). Analysis by an electronic tongue instrument showed that BPAH-AGEs and BPCH-AGEs had bitterness scores that were significantly (p < 0.05) less than quinine. The addition of BPAH-AGEs or BPCH-AGEs to quinine led to significant (p < 0.05) reductions (up to 38%) in bitterness intensity of quinine. The use of 3% hydrolysate to react with glucose yielded glycated peptides with a stronger ability to reduce quinine bitterness than when 1% was used. Calcium release from HEK293T cells stably expressing the T2R4 human bitter taste receptor was significantly (p < 0.05) attenuated by BPAH-AGEs (up to 96%) and BPCH-AGEs (up to 92%) when compared to the BPAH (62%) and BPCH (3%) or quinine (0%). We concluded that BPAH-AGEs and BPCH-AGEs may be used as bitter taste blockers to formulate better tasting foods.Entities:
Keywords: Maillard reaction; T2R4; advanced glycation end products; beef; bitterness intensity; electronic tongue; protein hydrolysate; quinine
Mesh:
Substances:
Year: 2019 PMID: 31509959 PMCID: PMC6770518 DOI: 10.3390/nu11092166
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Compounds with known bitter scores from a human sensory analysis panel *.
| Compounds | Used to Build Bitterness Standard Model | Used to Validate Bitterness Standard Model | Concentration (mM) | Published Values |
|---|---|---|---|---|
| Caffeine | √ | 0.24 | 2.5 | |
| Quinine | √ | 0.03 | 9 | |
| Prednisolone | √ | 0.44 | 13.5 | |
| Paracetamol | √ | 3.31 | 4 | |
| Loperamide | √ | 0.002 | 7.5 | |
| Famotidine | √ | 0.06 | 4.2 |
* Source: Alpha MOS [24].
Degree of glycation (DG) for alcalase hydrolysate and chymotrypsin hydrolysate advanced glycation end products (AGEs).
| Hydrolysate Concentration (%) | Glucose Concentration (M) | DG (%) * | |
|---|---|---|---|
| Alcalase AGEs | Chymotrypsin AGEs | ||
| 1 | 0.1 | 46.67 a | 29.53 a |
| 1 | 0.2 | 47.53 b | 29.11 a |
| 1 | 0.3 | 54.15 e | 30.13 b |
| 1 | 0.4 | 54.57 f | 36.67 d |
| 1 | 0.5 | 56.45 g | 37.14 e |
| 3 | 0.1 | 48.00 c | 29.49 a |
| 3 | 0.2 | 48.29 c | 28.86 a |
| 3 | 0.3 | 48.68 d | 36.63 cd |
| 3 | 0.4 | 54.88 f | 36.40 c |
| 3 | 0.5 | 54.96 fg | 38.60 f |
* Mean of triplicate replications. For each column, mean values with different alphabets are significantly different (p < 0.05).
Figure 1Estimated electronic tongue bitter scores of glycated protein hydrolysates and their ability to suppress quinine bitterness intensity: AH-AGEs, glycated alcalase hydrolysate (A); (B) CH-AGEs, glycated chymotrypsin hydrolysate (B). BCML (Nα, Nα-bis(carboxymethyl)-Llysine) was used as a positive control. Bars with different letters have significantly different (p < 0.05) mean values as determined from Duncan Multiple Range tests while error bars represent standard deviation.
Bitter intensity level with corresponding scores from the human taste evaluation panelists *.
| Intensity | Range |
|---|---|
| Taste not detected | 1–4.5 |
| Slight taste | 4.5–8.5 |
| Acceptable | 8.5–12.5 |
| Acceptable limit | 12.5–16.5 |
| Not acceptable | 16.5–20.0 |
* Used to build the bitterness standard model [24].
Figure 2Calcium mobilization in T2R4 expressing HEK293T cell system after treatment with protein hydrolysates, glycated protein hydrolysates (5 mg/mL) and quinine (1 mM): A. alcalase hydrolysate (AH), 1% AH + 0.3 M D-glucose (A1), 3% AH + 0.3 M D-glucose (A2), 1% AH + 0.4 M D-glucose (A3), 3% AH + 0.4 M D-glucose (A4), 1% AH + 0.5 M D-glucose (A5), 3% AH + 0.5 M D-glucose (A6); B. chymotrypsin hydrolysate (CH), 1% CH + 0.1 M D-glucose (C1), 3% CH + 0.1 M D-glucose (C2), 3% CH + 0.2 M D-glucose (C3), 3% CH + 0.3 M D-glucose (C4), 3% CH + 0.4 M D-glucose (C5), 3% CH + 0.5 M D-glucose (C6). Bars with different letters have significantly different (p < 0.05) mean values as determined from Duncan Multiple Range tests while error bars represent standard deviation. ΔRFU: changes in relative fluorescence unit (test cells minus control cells).